Outcome (studies)
Improvement
Relative risk · 95% CI
00.511.5+
← P2Et
reduces riskIncreased
risk →
reduces riskIncreased
risk →
P2Et for COVID-19
1
study with
91
patients
Serious outcome risk
No significant improvements are seen in meta-analysis to date.
COVID-19 P2Et studies · November 2026
|
Outcome (studies)
Improvement
Relative risk · 95% CI
00.511.5+
← P2Et
reduces riskIncreased risk → |
Sep 8 2022 |
et al., Frontiers in Medicine, doi:10.3389/fmed.2022.991873 | Randomized double-blind clinical study in patients with COVID-19 to evaluate the safety and efficacy of a phytomedicine (P2Et) |
| 24% lower ICU admission (p=0.76) and 23% shorter hospitalization (p=0.12). RCT 91 hospitalized COVID-19 patients in Colombia showing no significant differences in clinical outcomes with P2Et treatment. P2Et treatment was associated with reduced pro-inflammatory cytokines (G-CSF, IL-5, IL-18) and increased NK cel.. | ||
